LLS TAP is a strategic venture philanthropy funding initiative to accelerate innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.
LLS TAP co-funds first-in-human and registration-enabling clinical trials ($500,000 - $9 Million equity or asset funding not to exceed 50%). Applications are accepted year-round and due diligence takes 3-6 months.
Since its inception in 2007, three LLS TAP-supported therapies have been approved by the FDA:
VyxeosTM, Yescarta® and ElzonrisTM
Currently, more than 20 LLS-supported assets are in clinical development including 5 in ongoing or planned registration-enabling studies. LLS TAP portfolio companies have a higher probability of partnering/M&A. This track record includes Gilead’s 2020 acquisition of Forty Seven Inc. for $4.9 Billion.
LLS leverages its over 70-year commitment to cures for blood cancers and has funded over 4000 academic grants and 60 TAP assets since its inception, amounting to $1.3 Billion of support toward disease control and cures. LLS knowledge and know-how in blood cancer drug development is unparalleled, underscored by LLS support for over 85% of the new blood cancer therapies approved in the past 20 years.
To learn more about TAP: https://www.lls.org/therapy-acceleration-program
To learn more about LLS-supported Research: https://www.lls.org/lls-funded-research
